Burnout is a syndrome resulting from chronic workplace stress that has not been successfully managed — characterized by exhaustion, cynicism/depersonalization, and reduced professional efficacy (WHO ICD-11; Maslach Burnout Inventory). Moral injury is the lasting psychological, biological, spiritual, behavioral, and social impact of perpetrating, failing to prevent, or witnessing acts that transgress one's moral beliefs and expectations (Litz 2009). Both are distinct from — but often overlapping with — post-traumatic stress disorder (PTSD), depression, and anxiety disorders. Healthcare workers, military personnel, first responders, and corrections officers are the populations most at risk. The COVID-19 pandemic dramatically elevated healthcare worker burnout and moral injury — Canadian Medical Association surveys document substantial physician burnout, and similar patterns extend to nurses, paramedics, ICU staff, long-term care workers. This article is a Canadian evidence-and-pathway guide for the specific population of healthcare workers, military, and first responders evaluating psychedelic-assisted therapy: distinctions between burnout, moral injury, and PTSD; emerging evidence for ketamine and psilocybin in occupational mental health populations; and the VAC, PSHCP, and WSIB pathways that determine practical access.

Key takeaways

Burnout = chronic workplace stress syndrome (WHO ICD-11; Maslach Burnout Inventory): exhaustion, cynicism/depersonalization, reduced efficacy. Not a DSM-5 diagnosis.

Moral injury = lasting psychological/biological/spiritual/behavioral/social impact of perpetrating, failing to prevent, or witnessing acts transgressing moral beliefs (Litz 2009). Distinct from PTSD though often co-occurring.

PTSD is the formal DSM-5 diagnosis for trauma-related symptoms — with established psychedelic-assisted therapy evidence (MDMA-AT, ketamine).

Healthcare workers, military, first responders, corrections officers are highest-risk populations.

Healthcare workers post-COVID: substantially elevated burnout/moral injury — physician CMA surveys, nursing organizations document widespread distress.

Military / veteran moral injury: widely recognized; VAC pathway includes service-related conditions.

First responder moral injury: Bill 163 Ontario presumptive PTSD covers eligible conditions; WCB Alberta Bill 27 parallels.

Treatment when meets criteria: PTSD, MDD, anxiety, SUD pathways apply when condition criteria are met. Psychedelic-assisted therapy as adjunct in carefully-screened cases.

Burnout alone (without comorbid DSM-5 condition) is not a typical psychedelic-assisted therapy indication — workplace structural change, recovery time, organizational interventions are foundational.

Defining the constructs

Burnout (WHO ICD-11)

WHO ICD-11 (2019 revision) categorizes burnout as an "occupational phenomenon" (not a medical condition):

Feelings of energy depletion or exhaustion
Increased mental distance from one's job; cynicism related to one's job
Reduced professional efficacy

Maslach Burnout Inventory (MBI) — most-used research measure across three subscales: emotional exhaustion, depersonalization, personal accomplishment.

Moral injury (Litz 2009)

Moral injury is the lasting psychological, biological, spiritual, behavioral, and social impact of perpetrating, failing to prevent, or witnessing acts that transgress one's moral beliefs and expectations.

Key features:

Emotional: guilt, shame, sense of unforgivability, betrayal
Spiritual: loss of trust in self, others, institutions, transcendent meaning
Distinct from PTSD: PTSD anchored in fear-based trauma; moral injury anchored in values-based transgression. Often co-occurring but distinguishable.

PTSD (DSM-5) — addressed in PTSD and Psychedelic-Assisted Therapy.

The high-risk populations

Healthcare workers: physicians, nurses, paramedics, allied health, social workers, ICU staff, long-term care workers. CMA surveys document substantial physician burnout.
Military personnel and veterans: combat exposure, sustained operations, moral injury exposure
First responders: police, firefighters, paramedics, 911 dispatchers, corrections officers
Other: humanitarian workers, journalists in conflict zones, child protection workers

The evidence map for psychedelic-assisted therapy

Off-label ketamine — emerging burnout/moral injury use

Limited published RCT evidence for burnout or moral injury as primary indication
Real-world Canadian KAP: ketamine has been used for healthcare workers, first responders, and military with comorbid TRD and/or PTSD
Effect on moral-injury-specific dimensions (guilt, shame, spiritual distress) is less well-characterized

Psilocybin — emerging

Bossis 2020 / others: psilocybin's mystical-experience-mediated effects on existential meaning may have relevance for moral injury — though direct moral-injury RCTs do not yet exist
Mechanism rationale: 5-HT2A psychological flexibility hypothesis applies to rigid moral-injury cognitions and shame; phase 2/3 evidence for moral-injury primary indication is not yet developed

MDMA-AT — relevant for moral-injury-PTSD comorbidity

Mitchell 2021/2023 MAPP1/MAPP2 PTSD trials included veterans with combat-related PTSD; moral-injury overlap is substantial
Mithoefer 2018: phase 2 in military veterans, firefighters, police officers
MDMA-AT shows particular relevance for the moral-injury-PTSD overlap population

Spravato — TRD only

Spravato is approved for TRD only. Healthcare workers, military, or first responders with TRD meet criteria for Spravato through standard pathways.

For more detail see MDMA-Assisted Therapy for Veterans, PTSD and Psychedelic-Assisted Therapy, and Treatment-Resistant Depression and Psychedelic-Assisted Therapy.

Decision framework — burnout vs moral injury vs PTSD

Step	Question	Consequence
1	Comprehensive psychiatric assessment — does the patient meet DSM-5 criteria for PTSD, MDD, anxiety, SUD?	If yes: standard condition pathways apply
2	Is the primary issue burnout without DSM-5 condition?	Workplace structural change, recovery time, organizational interventions are foundational; psychedelic-assisted therapy is rarely first-line
3	Is moral injury the dominant feature?	Specialized moral-injury psychotherapy (Adaptive Disclosure, Building Spiritual Strength) plus comorbid condition treatment
4	What's the population?	Veterans → VAC; first responders → Bill 163/WCB; healthcare workers → varying provincial mental health programs + private

Canadian access pathways

Healthcare workers

Provincial physician health programs: Ontario Medical Association OMA Physician Health Program, AMA Physician and Family Support Program, Doctors of BC PHP, Quebec Programme d'Aide aux Médecins du Québec
Nursing organizations offer parallel mental health resources
Private psychotherapy and psychiatry: typically via private extended health benefits
Spravato: covered through PSHCP (Public Service Health Care Plan) / private insurance prior auth where TRD (treatment-resistant depression) criteria met
Off-label ketamine: typically out-of-pocket
Psilocybin SAP: case-by-case for SAP-eligible conditions

Military / veterans (VAC)

VAC (Veterans Affairs Canada) mental-health benefits: cover service-related conditions
Ketamine therapy: established case-by-case
MDMA-AT: case-by-case for service-related PTSD where SAP-approved
Psilocybin: not covered

First responders

Bill 163 Ontario (expanded October 2024): presumptive PTSD coverage for designated first responders
WCB Alberta Bill 27 (2018): presumptive PTSD for first responders
WSIB (Ontario's Workplace Safety and Insurance Board) five specialty formularies: cover ketamine and esketamine

What the evidence does NOT say

Psychedelic-assisted therapy is NOT a substitute for organizational change in burnout. Workplace structural factors — workload, autonomy, support, fairness, values alignment, recognition — are foundational.
Burnout alone (without DSM-5 condition) is not a typical psychedelic-assisted therapy indication.
Moral injury evidence base is still developing. Specialized moral-injury psychotherapy (Adaptive Disclosure, Building Spiritual Strength, accelerated resolution therapy) has more direct moral-injury evidence than psychedelic-assisted therapy.
Self-medication risks: healthcare workers face occupational risk for SUD related to self-medication; psychedelic-assisted therapy provided without comprehensive screening can compound.
Confidentiality concerns: healthcare workers, military, first responders may have professional registration / clearance considerations; honest discussion with the clinical team is important.
Recovery time, peer support, organizational change are foundational structural responses to burnout and moral injury.

How ATMA CENA works with healthcare workers, military, first responders

ATMA CENA follows a careful clinical pathway:

Comprehensive intake: occupational context, trauma exposures, screening for PTSD/MDD/anxiety/SUD, professional registration considerations
Confidentiality framing: standard clinical confidentiality; discuss specific professional registration considerations
Distinguish burnout vs moral injury vs PTSD: route to appropriate evidence-based care
Three-phase model: preparation + dosing + integration
Coordinated care: existing therapeutic relationships preserved
Honest framing: ATMA CENA will route burnout-only patients to organizational interventions, recovery time, and peer support before psychedelic-assisted therapy

See also MDMA-Assisted Therapy for Veterans for more detail on the veteran pathway.

Frequently asked questions

What's the difference between burnout, moral injury, and PTSD? Burnout = chronic workplace stress syndrome (WHO ICD-11, not DSM-5): exhaustion, cynicism, reduced efficacy. Moral injury = lasting psychological/spiritual/social impact of perpetrating, failing to prevent, or witnessing acts that transgress moral beliefs (Litz 2009). PTSD = formal DSM-5 diagnosis for trauma-related symptoms. Often overlapping but distinguishable.

Can psychedelic-assisted therapy treat burnout? Burnout alone (without DSM-5 condition) is not a typical psychedelic-assisted therapy indication. Workplace structural change, recovery time, peer support, organizational interventions are foundational. When burnout has progressed to comorbid TRD, anxiety, or PTSD, those condition pathways apply.

What about moral injury specifically? Specialized moral-injury psychotherapy (Adaptive Disclosure, Building Spiritual Strength, accelerated resolution therapy) has more direct moral-injury evidence. Psychedelic-assisted therapy for moral injury primary indication is investigational. MDMA-AT may be relevant for moral-injury-PTSD overlap populations.

What about healthcare workers post-COVID? Post-pandemic burnout/moral injury elevation is well-documented in CMA surveys, nursing organizations. Provincial physician health programs and parallel resources are first-line. When DSM-5 condition criteria are met, condition pathways apply (e.g., TRD → Spravato; PTSD → MDMA-AT SAP).

What about military or veterans? VAC mental-health benefits cover service-related conditions. Ketamine established; MDMA-AT case-by-case for SAP-approved PTSD; psilocybin not covered. Moral-injury-PTSD overlap is well-recognized.

What about first responders? Bill 163 Ontario presumptive PTSD coverage for designated first responders; WCB Alberta Bill 27 parallels. WSIB covers ketamine and esketamine for compensable conditions.

Are healthcare worker registration / clearance concerns at issue? Possibly — depending on profession and jurisdiction. Honest discussion with the clinical team about confidentiality and any professional registration considerations is important. Standard clinical confidentiality applies.

What's the role of organizational change? Foundational. Burnout drivers — workload, autonomy, support, fairness, values alignment, recognition — are workplace-structural. Individual treatment cannot fully compensate for unfixed organizational drivers.

What if I have suicidality? Severe suicidality requires comprehensive psychiatric care. Healthcare worker, military, and first responder populations have substantial occupational suicidality risk. Crisis resources (Talk Suicide Canada 1-833-456-4566) are first-line.

Are there Canadian trials I can join? Various Canadian institutions run PTSD-related trials with healthcare worker, military, and first responder populations. ATMA CENA's clinical team can route patients to relevant active trials.

Sources

Litz BT, Stein N, Delaney E, et al. (2009). Moral injury and moral repair in war veterans: a preliminary model and intervention strategy. Clin Psychol Rev, 29(8):695-706. PMID: 19683376.
Maslach C, Schaufeli WB, Leiter MP. (2001). Job burnout. Annu Rev Psychol, 52:397-422. PMID: 11148311.
World Health Organization — ICD-11 burnout: https://www.who.int/news/item/28-05-2019-burn-out-an-occupational-phenomenon-international-classification-of-diseases
Mithoefer MC, Mithoefer AT, Feduccia AA, et al. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers. Lancet Psychiatry, 5(6):486-497. PMID: 29728331.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: phase 3 (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Currier JM, Holland JM, Drescher KD. (2014). Residential treatment for combat-related posttraumatic stress disorder: identifying trajectories of change and predictors of treatment response. PLoS One, 9(7):e101741. PMID: 25011117.
Canadian Medical Association — Physician Health: https://www.cma.ca/our-focus/physician-wellness
Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
WSIB Ontario — PTSD First Responders Policy: https://www.wsib.ca/en/operational-policy-manual/posttraumatic-stress-disorder-first-responders-and-other-designated
WCB Alberta — Bill 27 / first responder presumptive PTSD: https://www.wcb.ab.ca/
Talk Suicide Canada (24/7): 1-833-456-4566 — https://talksuicide.ca/
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Last updated: 2026-05-06

Burnout, Moral Injury, and Psychedelic-Assisted Therapy in Canada

Access and legality vary by jurisdiction